Fructose and liver health in fatty liver disease
Part of Digestive system clinical trials.
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 45 and 65 years old
- You are overweight according to adjusted BMI guidelines for your ethnic group
- You have been diagnosed with MASH (a serious form of fatty liver disease) with moderate liver scarring (F2-F3), or you have fatty liver without significant scarring, or you are a healthy volunteer without fatty liver
- You do not have diabetes, and your average blood sugar (HbA1c) is below a certain level
- You are not a heavy drinker, smoker, or taking certain medications like steroids, antibiotics, or weight loss drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This study screens participants for MASH (a type of liver fat inflammation) using information about your health and risk factors. It may help you and your care team learn whether you could have MASH and need follow-up.
This study tests a new blood test to help diagnose fatty liver disease and liver fibrosis. It aims to see how well the test works compared with a liver biopsy. Your participation could help improve diagnosis for others.
This study looks at whether certain gene activity in people with fatty liver disease can predict the risk of developing colorectal polyps. It may help doctors find high-risk patients earlier.
This study tests whether a supplement called betaine can reduce liver fat and damage in people with a type of fatty liver disease that includes inflammation. Half of the participants will receive betaine, and half will receive a placebo (a pill with no active ingredient).
This study looks at how the body handles fructose (a natural sugar) in people with different weights. It may help explain why some people process sugars differently.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.